Khosla Ventures Acquisition Co

Khosla Ventures Acquisition Co. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses for its initial business. The company was founded in 2004 by Vinod Khosla and is headquartered in Menlo Park, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Khosla Ventures Acquisition Co. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses for its initial business. The company was founded by Vinod Khosla and Kaul Samir in 2004 and is headquartered in Menlo Park, CA.

MENLO PARK, Calif. , Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (Nasdaq: KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023.

Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution

Chevron

United Continental Hlds

Although still in its infancy, the global market for sodium-ion batteries is expected to be worth over $11 billion by 2033.

Here's why sodium-ion batteries are shaping up to be a big technology breakthrough

BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (Nasdaq: KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately.

Valo Health and Khosla Ventures Acquisition Co. Mutually Agree to Terminate Business Combination Agreement

BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (Nasdaq: KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.

Valo Health and Khosla Ventures Acquisition Co. Announce Additional PIPE Commitments

BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (Nasdaq: KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health").

Khosla Ventures Acquisition Co. Announces Planned Transfer of Listing to NYSE in Connection with its Proposed Business Combination with Valo Health

BOSTON and MENLO PARK, Calif., Oct. 25, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (Nasdaq:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the Special Meeting of Stockholders ("Special Meeting") to vote on the approval and adoption of KVSA's business combination agreement with Valo Health, LLC ("Valo Health") and the wholly owned subsidiary of Valo Health, Valo Health, Inc. ("Valo"), will be held via live telecast on November 16, 2021 at 10:00 a.m.

Khosla Ventures Acquisition Co. announces Special Meeting of Stockholders to approve business combination with Valo Health

Khosla Ventures Acquisition is combining with Valo Health in a ~$2.8B EV de-SPAC deal. Valo Health is a pre-revenue drug discovery platform that has high risk-reward characteristics.

Khosla Ventures/Valo Health De-SPAC: Heed The Sponsor's Advice And Stay Away

Boston-based Valo Health LLC has agreed to go public through a reverse merger with a blank-check firm backed by venture capitalist Vinod Khosla, in a deal valuing the combined company at about $2.8 billion. Founded in 2019, Valo Health is a biotech company that uses data analysis and artificial intelligence to help drug discovery and development.

Valo Health To Combine With Vinod Khosla-Backed SPAC In $2.8B Deal

Khosla Ventures Acquisition Co. (NASDAQ: KVSA), a special purpose acquisition vehicle (SPAC), and Valo Health LLC, a technology startup company, have entered into a definitive merger agreement to combine and take Valo Health public. Valo is a Boston-headquartered technology company that aims to accelerate the drug discovery and development process using its Opal Computational Platform […] The post The latest SPAC deal to know about: Valo Health to combine with Khosla Ventures Acquisition appeared first on Invezz.

The latest SPAC deal to know about: Valo Health to combine with Khosla Ventures Acquisition

BOSTON, June 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. ("KVAC") (NASDAQ: KVSA), a special purpose acquisition company founded by affiliates of Khosla Ventures, LLC, announced today that they have entered into a definitive merger agreement.  A Flagship Pioneering company, Valo is building a fully-integrated, end-to-end approach to developing drugs from target discovery through approval using its Opal Computational Platform™.

Valo Health and Khosla Ventures Acquisition Co. to Combine and Create Publicly Traded Company Focused on Transforming the Drug Discovery and Development Process

News for Khosla Ventures Acquisition Co Stock (KVSA)